These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 18534850

  • 1. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
    Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y, Sugimura H.
    Breast; 2008 Oct; 17(5):523-7. PubMed ID: 18534850
    [Abstract] [Full Text] [Related]

  • 2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 3. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
    Zhao J, Wu YL, Wang YD, Zhao GR, Wang J.
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
    [Abstract] [Full Text] [Related]

  • 4. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.
    J Clin Oncol; 2007 Oct 01; 25(28):4423-30. PubMed ID: 17906205
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.
    J BUON; 2013 Oct 01; 18(1):57-63. PubMed ID: 23613389
    [Abstract] [Full Text] [Related]

  • 6. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O, Pintens S, Van Belle V, Van Huffel S, Camerlynck E, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Decock J, Hendrickx W, Weltens C, Van den Bogaert W, Vanden Bempt I, Drijkoningen M, Paridaens R, Wildiers H, Vergote I, Christiaens MR, Neven P.
    Breast Cancer Res Treat; 2009 May 01; 115(2):349-58. PubMed ID: 18629635
    [Abstract] [Full Text] [Related]

  • 7. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
    van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR.
    Cancer Treat Rev; 2011 Oct 01; 37(6):422-30. PubMed ID: 21177040
    [Abstract] [Full Text] [Related]

  • 8. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S.
    Radiat Med; 2005 May 01; 23(3):189-94. PubMed ID: 15940066
    [Abstract] [Full Text] [Related]

  • 9. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.
    J Clin Oncol; 2008 Mar 01; 26(7):1059-65. PubMed ID: 18227529
    [Abstract] [Full Text] [Related]

  • 10. [The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].
    Wang S, Zhang JQ, Qiao XM, Yang DQ, Tong FZ, Liu HJ.
    Zhonghua Wai Ke Za Zhi; 2005 Aug 01; 43(15):1011-3. PubMed ID: 16194363
    [Abstract] [Full Text] [Related]

  • 11. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar 01; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 12. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P, Liu T, Wang Y, Shao S, Zhang W, Lv Y, Yi J, Wang Z.
    Clin Breast Cancer; 2013 Feb 01; 13(1):53-60. PubMed ID: 23103368
    [Abstract] [Full Text] [Related]

  • 13. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O, Chen F, Wiley EL, Keswani A, Diaz LK, Memmel HC, Rademaker A, Gradishar WJ, Morrow M, Khan SA, Cryns VL.
    Breast Cancer Res Treat; 2008 Oct 01; 111(3):411-7. PubMed ID: 17968656
    [Abstract] [Full Text] [Related]

  • 14. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 01; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 15. Relation between pathomorphological response in tumors after neoadjuvant chemotherapy and clinico-morphological and molecular prognostic factors in patients with breast cancer.
    Timovska YO, Pivnyuk VM, Oliynichenko GP, Anikushko MF, Zachartseva LM, Chekhun VF.
    Exp Oncol; 2009 Dec 01; 31(4):231-6. PubMed ID: 20010529
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G, Beadle G, Thomas S, Mengersen K, Stein S.
    Pathology; 2006 Oct 01; 38(5):391-8. PubMed ID: 17008275
    [Abstract] [Full Text] [Related]

  • 17. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
    Wang B, Guan ZZ, Liu DG, Lin TY, Zhang L, Xia ZJ, Teng XY.
    Ai Zheng; 2004 Dec 01; 23(12):1710-3. PubMed ID: 15601567
    [Abstract] [Full Text] [Related]

  • 18. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

  • 19. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
    Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC.
    Breast J; 2008 Jun 01; 14(2):141-6. PubMed ID: 18248553
    [Abstract] [Full Text] [Related]

  • 20. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA, Mamoon N, Mushtaq S, Khadim MT.
    J Coll Physicians Surg Pak; 2009 Feb 01; 19(2):99-103. PubMed ID: 19208313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.